Tillkännagivande • Jun 19
Apontis Pharma AG, Annual General Meeting, Jul 29, 2025 Apontis Pharma AG, Annual General Meeting, Jul 29, 2025, at 10:00 W. Europe Standard Time. Tillkännagivande • Nov 21
Shares of Apontis Pharma to Delist Following the Tender Offer Zentiva said on November 19, 2024 that it has lifted the minimum acceptance threshold of 65% in its tender offer to acquire Germany's Apontis Pharma AG. Zentiva launched the offer in October, proposing EUR 10 per share. The planned deal values Apontis Pharma at EUR 85 million. Following the tender offer, Apontis Pharma shares will no longer be traded on the open market. A separate delisting bid will not be required, Zentiva said. Price Target Changed • Nov 15
Price target decreased by 9.4% to €15.75 Down from €17.38, the current price target is an average from 4 analysts. New target price is 61% above last closing price of €9.76. The company is forecast to post earnings per share of €0.12 next year compared to a net loss per share of €1.36 last year. Tillkännagivande • Oct 24
Zentiva AG initiated a tender offer to acquire 62.50% stake in Apontis Pharma AG (XTRA:APPH). Zentiva AG initiated a tender offer to acquire 62.50% stake in Apontis Pharma AG (XTRA:APPH) on October 24, 2024. A cash consideration valued at €10 per share will be paid by Zentiva AG. As part of consideration, an undisclosed value is paid towards common equity of Apontis Pharma AG. Through a German unit, Zentiva is offering €10 per share, which represents a premium of 52.9% over the closing price on October 15, or a day before the transaction was first announced. Apontis management and supervisory boards welcome the offer and plan to recommend shareholders to accept it. The Offer values APONTIS PHARMA at €85 million for 100% of share capital. Both the Management Board and the Supervisory Board of APONTIS PHARMA welcome the Offer. Subject to review of the Offer Document and in compliance with their fiduciary duties, both the Management Board and the Supervisory Board intend to support the Offer and to recommend all APONTIS PHARMA shareholders to accept the Offer. They have already confirmed that they will tender any APONTIS PHARMA shares held by them into the Offer. Zentiva and Paragon, the main shareholder of APONTIS PHARMA, have entered into a share sale and purchase agreement with respect to its stake of approx. 37.5% of APONTIS PHARMA shares at a cash consideration in the amount of EUR 9.00 per share, emphasizing the attractiveness of the offer price. Settlement of the Offer will be subject to customary offer conditions, including regulatory clearances. It also includes a minimum acceptance threshold of 65% of APONTIS PHARMA shares. The transaction is expected to close at the end of Q4 2024 or in Q1 2025. Reported Earnings • Aug 14
First half 2024 earnings released: EPS: €0.084 (vs €0.42 loss in 1H 2023) First half 2024 results: EPS: €0.084 (up from €0.42 loss in 1H 2023). Revenue: €22.7m (up 19% from 1H 2023). Net income: €702.8k (up €4.22m from 1H 2023). Profit margin: 3.1% (up from net loss in 1H 2023). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 42 percentage points per year, which is a significant difference in performance. Price Target Changed • Apr 15
Price target increased by 15% to €17.50 Up from €15.17, the current price target is an average from 3 analysts. New target price is 108% above last closing price of €8.40. Stock is down 22% over the past year. The company is forecast to post earnings per share of €0.12 next year compared to a net loss per share of €1.36 last year. Price Target Changed • Apr 13
Price target increased by 10% to €16.17 Up from €14.67, the current price target is an average from 3 analysts. New target price is 92% above last closing price of €8.40. Stock is down 24% over the past year. The company is forecast to post earnings per share of €0.13 next year compared to a net loss per share of €1.36 last year. New Risk • Apr 06
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Market cap is less than US$100m (€65.0m market cap, or US$70.4m). Reported Earnings • Mar 28
Full year 2023 earnings released Full year 2023 results: Revenue: €38.7m (down 31% from FY 2022). Net loss: €11.3m (down €14.0m from profit in FY 2022). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Major Estimate Revision • Nov 12
Consensus EPS estimates fall by 23% The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from €38.6m to €36.7m. Losses expected to increase from €1.01 per share to €1.24. Pharmaceuticals industry in Germany expected to see average net income growth of 25% next year. Consensus price target down from €19.00 to €16.13. Share price rose 5.7% to €3.52 over the past week. Price Target Changed • Nov 10
Price target decreased by 15% to €16.13 Down from €19.00, the current price target is an average from 3 analysts. New target price is 358% above last closing price of €3.52. Stock is down 55% over the past year. The company is forecast to post a net loss per share of €1.08 compared to earnings per share of €0.32 last year. Tillkännagivande • Nov 09
Apontis Pharma Provides Earnings Guidance for the Full Year 2023 Apontis Pharma provides earnings guidance for the full year 2023. The company expects sales of EUR 36.1 million. Valuation Update With 7 Day Price Move • Aug 03
Investor sentiment deteriorates as stock falls 32% After last week's 32% share price decline to €5.62, the stock trades at a trailing P/E ratio of 17.4x. Average forward P/E is 19x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 53% over the past year. Major Estimate Revision • Aug 01
Consensus EPS estimates fall by 81% The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from €42.6m to €38.6m. Losses expected to increase from €0.56 per share to €1.01. Pharmaceuticals industry in Germany expected to see average net income decline 0.7% next year. Consensus price target down from €25.54 to €20.50. Share price fell 31% to €5.62 over the past week. Tillkännagivande • Jul 29
Apontis Pharma AG to Report First Half, 2023 Results on Aug 10, 2023 Apontis Pharma AG announced that they will report first half, 2023 results on Aug 10, 2023 Valuation Update With 7 Day Price Move • Jul 04
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €8.96, the stock trades at a trailing P/E ratio of 27.8x. Average forward P/E is 18x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 21% over the past year. Tillkännagivande • Jun 29
Aontis Pharma AG Launches Single Pill Finder and Distribution of Single Pill Rosazimib APONTIS PHARMA AG launched Single Pill Finder and distribution of Single Pill Rosazimib - First of three launches in 2023. Single Pill Finder online application shows real-time options to simplify therapy. Free-of-charge physician assistance system for convenient continuation of loose combination as Single Pill. New Single Pill Rosazimib on the market. Further Single Pills to be marketed in 2023. Single Pills combine the established active ingredients in a single tablet in a daily single dose compared to loose combination therapy. The reduced number of tablets can increase adherence and thus contribute to improving prognosis, as demonstrated in the retrospective START and START 2.0 studies and the prospective SECURE study, among others. In addition, the new Single Pill Rosazimib is now available on the market, bringing the portfolio of already approved products in Germany to 11 Single Pills. As an online physician assistance system, the free-of-charge Single Pill Finder shows possible Single Pill options for simplifying therapy for patients on polymedication. Based on the existing nationally standardized medication plan for loose combination preparations, the physician receives real-time recommendations for substitution with Single Pills. The medication plan can be entered in manually, as a photo or uploaded as a scan via desktop, tablet, or smartphone. The results are presented in a smart sort order according to the degree to which the therapy can be simplified, e.g., the portion of single tablet substitutions. This makes it much easier for physicians to access solutions for simplifying therapies. The development for use under practice conditions was carried out with the participation of more than 400 physicians in Germany, according to the motto " by physicians for physicians". Launch of new Single Pill RosazIMib (AP - D01) continues APONTIS PHARMA's announced Single Pill portfolio expansion, providing substitution therapy for the loose combination of Rosuvastatin and Ezetimibe. Launched on 28 June 2023, indications include primaryhypercholesterolemia/homozygous familial hypercholesterolemia (HoFH) and prevention of cardiovascular events in patients with a history of coronary artery disease (CAD) and acute coronary syndrome. Price Target Changed • May 06
Price target decreased by 9.4% to €25.67 Down from €28.33, the current price target is an average from 3 analysts. New target price is 262% above last closing price of €7.10. Stock is down 52% over the past year. The company is forecast to post earnings per share of €0.07 for next year compared to €0.32 last year. Major Estimate Revision • May 04
Consensus revenue estimates decrease by 18%, EPS upgraded The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from €51.9m to €42.4m. EPS estimate increased from €0.067 to €0.07 per share. Net income forecast to shrink 70% next year vs 3.9% growth forecast for Pharmaceuticals industry in Germany . Consensus price target of €26.67 unchanged from last update. Share price fell 39% to €6.90 over the past week. Valuation Update With 7 Day Price Move • May 03
Investor sentiment deteriorates as stock falls 37% After last week's 37% share price decline to €6.98, the stock trades at a forward P/E ratio of 100x. Average forward P/E is 20x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 52% over the past year. Reported Earnings • Apr 02
Full year 2022 earnings released Full year 2022 results: Revenue: €58.4m (up 14% from FY 2021). Net income: €2.69m (up €3.43m from FY 2021). Profit margin: 4.6% (up from net loss in FY 2021). The move to profitability was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany. Valuation Update With 7 Day Price Move • Feb 21
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to €9.52, the stock trades at a forward P/E ratio of 45x. Average forward P/E is 17x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 40% over the past year. Valuation Update With 7 Day Price Move • Nov 10
Investor sentiment improved over the past week After last week's 18% share price gain to €7.16, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 15x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 68% over the past year. Tillkännagivande • Jul 06
Apontis Pharma AG Rolls Out New Single Pill for Secondary Prophylaxis Apontis Pharma AG announced the rollout of the Single Pill RosuASS in July. With this Single Pill, APONTIS PHARMA addresses the secondary prophylaxis of the group of patients with cardiovascular events in Germany and has thus been able to realize all three targeted market rollouts in financial year 2022. A potential patient group of more than 100,000 people results accordingly for the new Single Pill, which combines the active ingredients rosuvastatin and acetylsalicylic acid (ASA) for the first time on the German market. APONTIS PHARMA anticipates a medium-term annual sales potential for RosuASS of EUR 2.5 million. Stroke and myocardial infarction are often consequences of high blood pressure and/or disorders of lipid metabolism. Patients who develop a second heart attack or stroke have a significantly increased risk of mortality. Therefore, an important treatment goal for these patients is to prevent a recurrence of a cardiovascular event through appropriate therapeutic measures in so-called secondary prophylaxis. Here, medication usually requires the administration of several different substances, which results in the use of a large number of individual medications. However, as the number of tablets increases, so does the risk that they will not be taken reliably - which in turn increases the risk of a recurrence of heart attack and stroke. Withthe combination preparation RosuASS, APONTIS PHARMA supports patients' therapy in a far more efficient way. The clinical relevance of a Single Pill concept has been confirmed by the scientific "START" study, which ha been published in peer-reviewed publications such as Integrated Blood Pressure Control" and "Journal of Comparative Effectiveness Research". In total, data from 59,336 patients who received either a Single Pill or the identical loose combination were included in the analysis of the "START" study. Outcomes of Single Pill therapy included significantly higher treatment adherence, fewer cardiovascular events, lower all-cause mortality, fewer primary care physician visits, and lower total cost per patient. Tillkännagivande • May 26
Apontis Pharma AG Launches Two New Single Pills Apontis Pharma AG announced the launch of two of its compounds in the month of May 2022. With the single pills Tonotec Lipid and AmloAtor, APONTIS PHARMA is addressing the large group of patients with high blood pressure and lipid metabolism disorders in Germany and has already been able to realize two of the at least three planned market launches in the financial year 2022. For the two single pills, this results in a total potential patient group of around 750,000 people. APONTIS PHARMA anticipates a medium-term revenue potential for Tonotec Lipid of EUR 5.0 million and for AmloAtor of EUR 3.2 million. With the combination products Tonotec Lipid and AmloAtor, APONTIS PHARMA supports patients' therapy in a far more efficient way. Tonotec Lipid combines the active ingredients Ramipril, Amlodipine and Atorvastatin in a single pill. In the case of AmloAtor, it is Amlodipine and Atorvastatin. The efficient mode of action of Single Pill therapy was scientifically confirmed by the "START" study and published in the peer-reviewed publications "Integrated Blood Pressure Control" and "Journal of Comparative Effectiveness Research", among others. In total, data from 59,336 patients were included in the evaluation of the "START" study, which showed, among other results, significantly higher treatment adherence, a lower number of GP visits and lower total costs per patient. Tillkännagivande • May 12
Apontis Pharma AG Provides Revenue Guidance for the Year 2022 Apontis Pharma AG provided revenue guidance for the year 2022. For the year, the Executive Board confirms its forecast of an increase in revenues of 8% to EUR 55.3 million. Tillkännagivande • Apr 20
Apontis Pharma Ag Announces Publication of Data on the Pharmacoeconomics of the Unique Healthcare Research Study Called "START" APONTIS PHARMA AG announced the publication of data on the pharmacoeconomics of the unique healthcare research study called "START" in the peer-reviewed "Journal of Comparative Effectiveness Research". In the START study (Effect of Single pill combinations on Treatment Adherence and persistence as well as on clinical and pharmacoeconomic outcomes in the Real-world Treatment of hypertension, coronary heart disease, hyperlipidemia and in secondary prevention of cardiovascular events: A claims data analysis), total costs and medication costs per patient/year were compared between therapy with seven single pills and therapy with the respective loose combination of the corresponding single active pharmaceutical substances. The authors conclude that a single pill therapy approach leads to a reduction in total costs and in medication costs per patient/year compared with a multi pill therapy approach in cardiovascular patients. In total, data from 59,336 patients were included in the evaluation, leading to the following results in favor of Single Pill therapy, among others: significantly higher compliance (adherence to therapy), a lower number of visits to the general practitioner, a lower number of visits to specialists, a significantly lower number of days spent in hospital and a significantly lower length of stay in hospital, a lower number of days of incapacity to work, lower total costs per patient per year, lower medication costs per patient per year. Reported Earnings • Apr 02
Full year 2021 earnings: EPS misses analyst expectations Full year 2021 results: €0.088 loss per share (up from €0.18 loss in FY 2020). Revenue: €51.2m (up 30% from FY 2020). Net loss: €745.2k (loss narrowed 37% from FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates. Over the next year, revenue is forecast to grow 9.0%, compared to a 8.2% growth forecast for the pharmaceuticals industry in Germany. Tillkännagivande • Sep 15
Apontis Pharma AG Announces Launch of New Single Pill for More Efficient Treatment of Hypertension and Hyperlipidemia Apontis Pharma AG announced the signing of a new in-licensing agreement for a new Single Pill. The market launch in Germany is planned for early 2022. The medication addresses patients who are simultaneously affected by hypertension (high blood pressure) and hyperlipidemia (disorder of lipid metabolism). The objective is to increase adherence by combining two active ingredients in just one pill and thus achieve a more efficient therapy for patients. The success of the Single Pill therapy strategy was proven by the START study conducted in 2019. It showed that patients benefited from a Single Pill compared to a multi-pill regime with the same substances. Instead of taking several individual preparations, treatment with the combination of substances in a Single Pill, which combines up to three active substances, promises a much higher adherence to therapy. Consequently, medications are taken more reliably when the dosage form is limited to one pill. APONTIS PHARMA is also pursuing this proven approach with its latest product and is offering a large and steadily increasing number of patients treatment perspective that meets their needs. Overall, APONTIS PHARMA is addressing a group of around half a million people in Germany who, in the case of hypertension and hyperlipidemia, have so far been taking a loose combination of these two substances. Accordingly, APONTIS PHARMA and the new Single Pill are opening up a promising market environment. Tillkännagivande • May 19
Apontis Pharma AG has completed an IPO in the amount of €87.4 million. Apontis Pharma AG has completed an IPO in the amount of €87.4 million.
Security Name: Ordinary Bearer Shares
Security Type: Common Stock
Securities Offered: 4,600,000
Price\Range: €19
Discount Per Security: €0.76
Transaction Features: Sponsor Backed Offering 
